Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean Troyer

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Genomics|February 24, 2016
DNA methylation profiles in African American prostate cancer patients in relation to disease progressionRohina Rubicz, Shanshan Zhao, Milan Geybels, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 13, 2006
Obesity, adipokines, and prostate cancer in a prospective population-based studyJacques Baillargeon, Elizabeth A Platz, David P Rose, et al.
The Journal of Urology|June 18, 2011
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional studyJesse K McKenney, Jeff Simko, Michael Bonham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2016
Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate CancerShanshan Zhao, Milan S Geybels, Amy Leonardson, et al.
Molecular Oncology|February 2, 2017
Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancerRohina Rubicz, Shanshan Zhao, Jonathan L Wright, et al.
European Urology Focus|September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerTamara L Lotan, Wei Wei, Carlos L Morais, et al.
The Prostate|June 30, 2018
A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancerShanshan Zhao, Amy Leonardson, Milan S Geybels, et al.
Clinical Chemistry|November 6, 2007
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample biasDale McLerran, William E Grizzle, Ziding Feng, et al.
Clinical Chemistry|November 21, 2007
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancerDale McLerran, William E Grizzle, Ziding Feng, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Genomics|February 24, 2016
DNA methylation profiles in African American prostate cancer patients in relation to disease progressionRohina Rubicz, Shanshan Zhao, Milan Geybels, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 13, 2006
Obesity, adipokines, and prostate cancer in a prospective population-based studyJacques Baillargeon, Elizabeth A Platz, David P Rose, et al.
The Journal of Urology|June 18, 2011
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional studyJesse K McKenney, Jeff Simko, Michael Bonham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2016
Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate CancerShanshan Zhao, Milan S Geybels, Amy Leonardson, et al.
Molecular Oncology|February 2, 2017
Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancerRohina Rubicz, Shanshan Zhao, Jonathan L Wright, et al.
European Urology Focus|September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerTamara L Lotan, Wei Wei, Carlos L Morais, et al.
The Prostate|June 30, 2018
A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancerShanshan Zhao, Amy Leonardson, Milan S Geybels, et al.
Clinical Chemistry|November 6, 2007
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample biasDale McLerran, William E Grizzle, Ziding Feng, et al.
Clinical Chemistry|November 21, 2007
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancerDale McLerran, William E Grizzle, Ziding Feng, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
Pageof 4